MicroRNA Expression Profiling in Psoriatic Arthritis

Andrea Pelosi,1 Claudio Lunardi,2 Piera Filomena Fiore,1 Elisa Tinazzi,2 Giuseppe Patuzzo,2 Giuseppe Argentino,2 Francesca Moretta,2 Antonio Puccetti,1,3 and Marzia Dolcino2

1Immunology Area, Pediatric Hospital Bambino Gesù, Viale San Paolo 15, 00146 Rome, Italy
2Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
3Department of Experimental Medicine, Section of Histology, University of Genova, Via G.B. Marsano, 16132 Genova, Italy

Correspondence should be addressed to Marzia Dolcino; marziadolcino@gmail.com

Received 5 September 2017; Revised 13 November 2017; Accepted 22 November 2017; Published 23 April 2018

Background. Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by bone erosions and new bone formation. MicroRNAs (miRNAs) are key regulators of the immune responses. Differential expression of miRNAs has been reported in several inflammatory autoimmune diseases; however, their role in PsA is not fully elucidated. We aimed to identify miRNA expression signatures associated with PsA and to investigate their potential implication in the disease pathogenesis.

Methods. miRNA microarray was performed in blood cells of PsA patients and healthy controls. miRNA pathway analyses were performed and the global miRNA profiling was combined with transcriptome data in PsA. Deregulation of selected miRNAs was validated by real-time PCR.

Results. We identified specific miRNA signatures associated with PsA patients with active disease. These miRNAs target pathways relevant in PsA, such as TNF, MAPK, and WNT signaling cascades. Network analysis revealed several miRNAs regulating highly connected genes within the PsA transcriptome. miR-126-3p was the most downregulated miRNA in active patients. Noteworthy, miR-126 overexpression induced a decreased expression of genes implicated in PsA.

Conclusions. This study sheds light on some epigenetic aspects of PsA identifying specific miRNAs, which may represent promising candidates as biomarkers and/or for the design of novel therapeutic strategies in PsA.

1. Introduction

Psoriatic arthritis (PsA) is characterized by inflammation of entheses and synovium, eventually leading to joint erosions and new bone formation [1].

PsA affects 10% to 30% of patients with skin psoriasis, with an estimated prevalence of 1% in the general population. Despite its association with skin psoriasis, PsA is considered a distinct clinical entity with a strong heritable component [2] and many genes have been implicated in conferring susceptibility to the disease [3]. However, only a limited number of genes have been linked to both psoriasis and PsA [3]. Several criteria have been proposed for the diagnosis and classification of PsA. Although none of them are universally accepted, the classification criteria proposed by Moll and Wright [4] and the more recent classification criteria for PsA (CASPAR) [5] are the most widely used.

The diagnosis of PsA is mainly performed on clinical features after the exclusion of other seronegative arthritides and no diagnostic tests are available so far.

The synovial tissue in PsA is characterized by an abundant T-cell infiltrate, by marked angiogenesis, and by synovial hyperplasia with increased secretion of cytokines and proteases, which may amplify the local inflammatory process eventually leading to joint destruction [6]. The cytokine tumor necrosis factor-alpha (TNF-alpha) is a very important inflammatory mediator and has been implicated in the pathogenesis of articular damage in PsA [6]. TNF-alpha inhibitors are therefore widely used in PsA therapy and are usually quite effective in reducing the extent of skin lesions and of musculoskeletal symptoms; however, a high percentage of PsA patients does not respond to TNF-alpha antagonists [1, 7]. Therefore, other cytokines have recently become targets of
MicroRNAs (miRNAs) are small noncoding RNAs that play an important role in the regulation of various biological processes through their interaction with cellular messenger RNAs [9]. Inflammatory responses have an impact on miRNAs expression, regulating their biogenesis by altering the transcription and processing of precursor transcripts or influencing stabilization of mature miRNAs [9]. In recent years, the number of miRNAs implicated in immune system development and function has dramatically enhanced, and there has been widespread discussion of their potential use as therapeutics for immunological diseases [9]. The concept that miRNAs participate in the pathogenesis of diseases, especially refractory diseases with unidentified mechanisms, might lead to a novel effective treatment. A number of studies have reported differential expression of miRNAs in several inflammatory autoimmune diseases, such as in rheumatoid arthritis (RA), multiple sclerosis, systemic lupus erythematosus, psoriasis, and systemic sclerosis [10]. These studies highlighted a deep implication of miRNAs as regulatory molecules in autoimmunity and the intriguing possibility of using miRNAs as disease biomarkers in these immunological disorders. In RA, miRNAs play an important role in inflammation, synovial cell proliferation, and production of matrix metalloproteases (MMP). Moreover, the expression level of several miRNAs in peripheral blood mononuclear cells (PBMC) correlates with RA disease activity [11].

As far as PsA concerns, little is known about miRNAs expression despite the relatively high prevalence of the disease. To date, only a study has explored blood miRNAs expression profile in a cohort of early active PsA patients [12]. Nevertheless, no high-throughput miRNA expression studies have been conducted to identify miRNAs specifically associated with the disease activity and no study has been so far performed which combines the analysis of blood microRNAs with transcriptional profiles in patients with PsA.

In the present study, we performed a miRNA microarray analysis on PBMCs of PsA patients at the active stage and in the remission phase of the disease. We found that distinct miRNA expression profiles are present in active and nonactive PsA patients as compared to healthy controls. Moreover, active and nonactive PsA patients are specifically identified by two different miRNA signatures. Pathway enrichment analysis on gene targets of deregulated miRNAs revealed signaling pathways typically implicated in PsA, such as TNF, mitogen-activated protein (MAP) kinase, and wingless related integration site (WNT) cascades.

The modular analysis of differentially expressed genes in PsA revealed pathogenetically relevant networks that are possibly targeted by the identified miRNAs. Among the modulated miRNAs, we found that miR-126-3p was downregulated in active PsA patients, whereas its expression was higher in nonactive patients. miR-126 overexpression induced a decrease of putative molecular targets with a potential role in PsA pathogenesis. This study sheds light on some aspects of PsA pathogenesis identifying deregulated miRNAs as promising candidates for the discovery of disease biomarkers and/or as molecular tools for designing novel therapeutic strategies in PsA.

2. Materials and Methods

2.1. Patients. We studied a cohort of 23 patients (12 males and 11 females, mean age: 53.5 years) affected by PsA, attending the Unit of Autoimmune Diseases, at the University Hospital of Verona, Italy. All patients fulfilled the CASPAR criteria for the diagnosis of PsA: inflammatory musculoskeletal involvement (inflammatory arthritis, enthesitis, or lumbar pain) combined with at least 3 features: (1) evidence of current psoriasis, personal history of psoriasis, and family history of psoriasis in unaffected patients; (2) affected nails (onycholysis, pitting); (3) dactylitis; (4) negative rheumatoid factor; and (5) radiographic evidence of new juxta-articular bone formation (excluding osteophytes) [5].

All the patients underwent clinical examination and laboratory evaluation comprehensive of inflammatory markers, such as C-reactive protein (CRP) and erythrocytes sedimentation rate (ESR); rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody detected by ELISA test; antinuclear antibody detected by indirect immunofluorescence on HeLa derived HEp-2 cells; and genetic screening for the association with the allele HLA-B27. All patients underwent the following instrumental investigations: ultrasonography with Power Doppler to investigate subclinical enthesopathy and synovitis in asymptomatic patients, conventional radiography, magnetic resonance imaging (MRI), and scintigraphy. The radiological features of peripheral PsA included asymmetric distribution, participation of distal interphalangeal joints, periostitis, bone density preservation, bone ankylosis, and pencil-in-cup deformity.

Patients were classified as active or in remission phase using the composite index Disease Activity in Psoriatic Arthritis (DAPSA) which takes into account the number of tender and swollen joints, CRP levels and patients’ assessment of general disease activity and pain using a visual analogic score (VAS). The disease was considered in remission when the score was <5. The patients in active phase bled before the beginning of treatment with anti-TNF agents and/or with disease-modifying antirheumatic drugs (DMARDs). Patients...
in remission were in maintenance treatment with biological agents and/or DMARDs.

A group of 9 subjects was selected within the entire cohort of PsA patients and utilized for the miRNA microarray study. The clinical features of the patients are reported in Table 1 that also includes a description of the PsA patients selected for the microarray study. 15 control healthy subjects matched for sex and age served as control group (7 males, 8 females). Moreover, 7 patients with rheumatoid arthritis (RA) were used as controls. RA patients had the American College of Rheumatology classification criteria for RA [13]. In all RA patients, the disease was at an active stage and blood was obtained before therapy with biological agents.

All the participants to the study signed a written informed consent. The local Ethical Committee of the University Hospital of Verona, Verona, Italy, had approved the study protocol. All the investigations have been performed according to the principles contained in the Helsinki declaration.

2.2. Microarray Analysis. Blood samples were collected in BD Vacutainer K$_3$EDTA tubes using a 21-gauge needle. PBMC were obtained upon stratification on Lympholyte® cell separation density gradient (Cedarlane, Burlington, Canada). Total RNA extraction from PBMCs was performed with miRNeasy mini kit following manufacturer’s protocol (Qiagen GmbH, Hilden, Germany). Samples hybridization and scanning were performed with miRNA Complete Labeling and Hyb Kit Protocol manual following the manufacturer provided protocols (Agilent Technologies, Santa Clara, CA, USA), by the Cancer Genomics Laboratory of Edo ed Elvo Tempia Valenta foundation (Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy). SurePrint Human miRNA Microarray Kit Release 21.0, 8x60K (Agilent Technologies), containing probes for 2549 miRNAs, was used. The Gene Spring software, version 14.8 (Agilent Technologies, Santa Clara, CA, USA), was used to background-adjust, normalize, and log-transform signals intensity. Quantile was used for between-array normalization. Relative miRNAs expression levels were validated applying the unpaired t-test ($p ≤ 0.01$) and the Bonferroni multiple testing correction. Finally, statistically significant miRNAs were chosen for final consideration when their expression was at least 1.5-fold different in the test sample versus control sample [log$_2$(fold change) > 0.5].

2.3. Pathway Enrichment Analysis of MicroRNA Targets. Pathway enrichment analysis was performed using the DIANA-Tarbase v. 7.0 and DIANA-miRPath server v3.0 (http://diana.imis.athena-innovation.gr) [14,15]. miRNA target genes identified by Tarbase were processed by miRPath to find enriched biological pathways provided by the Kyoto Encyclopedia of Genes and Genomes (KEGG) [15]. The analysis was performed using as “genes union” option. A $p$ value threshold of 0.05 and FDR correction were applied to the analysis. All identified pathways are arranged according to enrichment statistical scores ($p$ values) in addition to the number and names of miRNA target genes implicated in each KEGG pathway.

For the heat-map of Figure 3(a), the percentages of miRNA target genes for each biological process (BP) indicated were calculated as follows: the list of miRNAs targeting the BP of interest was obtained from the Gene Ontology (GO) reverse search function of miRPath v. 3.0. The module presents the list of miRNAs targeting the GO term of interest and the number of targeted genes for each miRNA (Tarbase v7.0 method). The percentage of target genes was calculated on the total number of human genes included in the GO term, as obtained from AmiGO 2 search tool in the Gene Ontology Consortium database (http://www.geneontology.org/).

2.4. Protein-Protein Interaction (PPI) Network Construction and Modular Analysis. Differentially expressed genes (DEGs) in PsA samples from our previous study [8] were mapped onto the STRING database [16] to detect protein-protein interactions (PPI) pairs validated by experimental studies. Network and modular analysis were carried out as we previously described [17].

2.5. Cell Cultures and Transfections. Human leukemic T-cell lymphoblast cell line Jurkat was purchased from European Collection of Authenticated Cell Cultures (clone E6.1, ECACC 88042803). Cells were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% (v/v) fetal bovine serum (FBS, South America, Gibco®; Thermo Fisher Scientific, Wilmington, DE, USA), L-Glutamine 1 mM, penicillin (200 U/mL), and streptomycin (100 mg/mL).

| Patients used for miRNA microarray study | 9 |
| Sex |  |
| Male | 5 |
| Female | 4 |
| Age at diagnosis | 53 ± 4.6 |
| Involvement |  |
| Axial | 3 |
| Peripheral | 6 |
| Enthesitis | 5 |
| Dactylitis | 3 |
| Psoriasis | 6 |
| Association with HLA-B27 | 4 |

Table 1: Clinical characteristics of PsA patients.
Jurkat cells were transfected by electroporation with Neon™ Transfection System (Thermo Fisher Scientific, Wilmington, DE, USA). Briefly, 2 × 10⁶ cells were electroporated in 100 μL tips (voltage: 1410 V, pulse width 30 ms, 1 pulse) with 60 pmol of miRIDIAN microRNA human hsa-miR-126-3p mimic or 60 pmol of miRIDIAN microRNA mimic negative control #2 (Dharmacon RNA Technologies, LaFayette, CO). 48 hours after transfection, cells were harvested and analyzed. Total RNA from Jurkat cells was obtained with miRNeasy mini kit (Qiagen, GmbH, Hilden, Germany).

2.6. **Real-Time PCR.** Mature miRNA expression was assayed by TaqMan® Advanced miRNA assays chemistry (Applied Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse-transcribed and preamplified with TaqMan Advanced miRNA cDNA synthesis kit following manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). 5 μL of 1:10 diluted cDNAs was amplified in 20 μL PCR reactions with 2x Fast Advanced Master Mix and TaqMan Advanced miRNA assays for hsa-miR-126-3p (477887_mir), hsa-miR-130a-3p (477851_mir), hsa-miR-151a-5p (478505_mir), or hsa-miR-148a-3p (477814_mir). As endogenous controls, we used hsa-miR-16-5p (477860_mir) and hsa-miR-26a-5p (477995_mir), since they are known to be expressed at relatively constant levels across many different tissues, including blood [18, 19]. We further confirmed stable expression patterns for miR-16-5p and miR-26a-5p across our samples (data not shown). The mean of CΔt values was used to normalize miRNA expression. Real-time PCR was carried out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems, Foster City, CA, USA). Expression values were obtained by ΔΔCt method using QuantStudio Real-Time PCR system software v.1.3.

For mRNA quantification in Jurkat cells, 500 ng of total RNA was treated with 1 unit of DNase I Amplification Grade (Invitrogen, Carlsbad, CA, USA) and then reverse-transcribed with random primers by using Super Script® IV first-strand synthesis system following manufacturer's instructions (Thermo Fisher Scientific, Wilmington, DE, USA). Real-time PCR were carried out in triplicate with PowerUp™ SYBR® Green reagent (Applied Biosystems, Foster City, CA, USA). Beta-Actin (ACTB) was used as endogenous control using the ΔΔCt method for comparing relative fold expression differences. The following primers were used: PKB2 (FW: 5'-CCAGAGCCAGATCCCTGTTG-3', RV: 5'-ATGGCTTGGTTCCTCATGAA-3'), AKT2 (FW: 5'-TGTCTATCCGGAGGCTGTG-3', RV: 5'-GGCTCCCATCTTGGCT-3'), PPP3CB (FW: 5'-TTATTTCCAGGAGGAGAGTTG-3', RV: 5'-ACAGTTTCCCTGTTTGG-3'), SDC2 (FW: 5'-CTCCCAAACTTCTGAGG-3', RV: 5'-TGCTGGAGTCTTGGCC-3'), ACTB (FW: 5'-ACCGAGGAGGATCCAC-3', RV: 5'-GGATAGCACGCGCTGGTATGCA-3').

### 3. Results

#### 3.1. **High-Throughput miRNA Expression Profiling in PBMCs of Psoriatic Arthritis.** In order to identify miRNA expression signatures associated with PsA, we analyzed global miRNA expression profiles by microarray in PBMCs derived from 5 patients with an active disease (active PsA), 4 patients in a remission phase (nonactive PsA), and 7 healthy age and sex matched donors (healthy). The clinical characteristics of patients included in the microarray study are reported in Table 1. When we compared active PsA samples with healthy controls, microarray analyses revealed 34 modulated miRNAs that satisfied the Bonferroni-corrected p value criterion (p ≤ 0.01) and the fold change criterion (FC ≥ 1.5), showing robust and statistically significant variation between PsA and healthy control samples. Among these 34 miRNAs, 21 were overexpressed and 13 underexpressed (Table 2). The comparison between nonactive PsA and healthy controls revealed 22 miRNAs significantly deregulated with 14 and 8 miRNAs over- and underexpressed, respectively (Table 3). The hierarchical clustering based on the significantly deregulated miRNAs showed a clear separation between active or nonactive PsA and healthy control groups, respectively (Supplementary Figure 1).

The lists of deregulated miRNAs in active and in nonactive PsA showed a partial overlap, with 12 miRNAs commonly deregulated in PsA samples. Moreover, all the overlapping miRNAs showed consensual modulation being over- or underexpressed in both active and nonactive disease (named PsA common subset). On the contrary, 22 miRNAs are differentially expressed only in active PsA (PsA only active), whereas 10 miRNAs were deregulated only in nonactive PsA samples (PsA only nonactive). These three subsets of differentially expressed miRNAs are listed in Figure I.

#### 3.2. **Pathway Enrichment Analysis of miRNAs Deregulated in PsA.** To investigate the molecular pathways potentially targeted by deregulated miRNAs in PsA, we performed a bioinformatic analysis using the miRNA pathway analysis web-server DIANA-miPath v.3 [15]. The software allows assessing the miRNA regulatory roles and the identification of controlled pathways based on predicted and/or validated miRNA target interactions. Since a major obstacle in the estimation of the functional impact of miRNAs on pathways is a high false discovery rate of miRNA target prediction algorithms, we focused our analyses only on experimentally validated miRNA targets included in DIANA-Tarbasa v.7.0 [14].

Thus, based on the validated gene targets, we performed KEGG molecular pathway analyses in the three previously identified subsets of differentially expressed miRNAs: PsA only active, PsA only nonactive, and PsA common. Of note, in all the miRNAs subsets we found a significant enrichment in several pathways that have already been described in PsA, such as pathways associated with proteoglycans metabolism [20]. Other KEGG pathways, significantly enriched, were related to the immune system and to signaling pathways regulating cell proliferation and/or apoptosis. These selected KEGG pathways for each miRNA subset are shown
Table 2: Differentially expressed miRNAs in PBMC from PsA patients with active disease compared to healthy controls.

| MicroRNA systematic name | miRBase accession number | Regulation | Fold change (log$_2$) | $p$ (corr) |
|--------------------------|--------------------------|------------|----------------------|-----------|
| hsa-miR-126-3p           | MIMAT0000445             | Down       | $-7.4133115$         | 0.00008   |
| hsa-miR-151a-5p          | MIMAT0004697             | Down       | $-5.9333086$         | 0.00017   |
| hsa-miR-130a-3p          | MIMAT0000425             | Down       | $-5.849619$          | 0.00831   |
| hsa-miR-4741             | MIMAT0019871             | Up         | 5.837836             | 0.00705   |
| hsa-miR-199a-3p          | MIMAT0000232             | Down       | $-5.6022415$         | 0.01055   |
| hsa-miR-451a             | MIMAT0001631             | Down       | $-5.4353294$         | 0.01516   |
| hsa-miR-3196             | MIMAT0015080             | Up         | 4.804034             | 0.01327   |
| hsa-miR-575              | MIMAT0003240             | Up         | 4.670869             | 0.00992   |
| hsa-miR-199a-5p          | MIMAT0000231             | Down       | $-4.415467$          | 0.00940   |
| hsa-miR-664b-5p          | MIMAT0022271             | Up         | 4.318427             | 0.00586   |
| hsa-miR-148a-3p          | MIMAT0000243             | Down       | $-3.969935$          | 0.00551   |
| hsa-miR-4787-5p          | MIMAT0019956             | Up         | 3.953499             | 0.00467   |
| hsa-miR-192-5p           | MIMAT0000222             | Down       | $-3.6372743$         | 0.01136   |
| hsa-miR-186-5p           | MIMAT0000456             | Down       | $-3.226546$          | 0.01406   |
| hsa-miR-6869-5p          | MIMAT0013802             | Up         | 4.510478             | 0.01528   |
| hsa-miR-199a-5p          | MIMAT0000231             | Down       | $-4.415467$          | 0.00940   |
| hsa-miR-664b-5p          | MIMAT0022271             | Up         | 4.318427             | 0.00586   |
| hsa-miR-148a-3p          | MIMAT0000243             | Down       | $-3.969935$          | 0.00551   |
| hsa-miR-4787-5p          | MIMAT0019956             | Up         | 3.953499             | 0.00467   |
| hsa-miR-192-5p           | MIMAT0000222             | Down       | $-3.6372743$         | 0.01136   |
| hsa-miR-186-5p           | MIMAT0000456             | Down       | $-3.226546$          | 0.01406   |
| hsa-miR-6869-5p          | MIMAT0027638             | Up         | 3.2232947            | 0.00811   |
| hsa-miR-423-5p           | MIMAT0004748             | Down       | $-2.135325$          | 0.01245   |
| hsa-miR-7704             | MIMAT0030019             | Up         | 2.0383425            | 0.00340   |
| hsa-miR-6089             | MIMAT0023714             | Up         | 2.0341978            | 0.00464   |
| hsa-miR-6775-5p          | MIMAT0027450             | Up         | 1.9994686            | 0.01461   |
| hsa-miR-6125             | MIMAT0024598             | Up         | 1.9778519            | 0.00284   |
| hsa-miR-1202             | MIMAT0005865             | Up         | 1.6242537            | 0.01527   |
| hsa-miR-331-3p           | MIMAT0000760             | Down       | $-1.4172684$         | 0.01484   |
| hsa-miR-4530             | MIMAT0019069             | Up         | 1.4050666            | 0.00092   |
| hsa-miR-6749-5p          | MIMAT0027398             | Up         | 1.3433247            | 0.00744   |
| hsa-miR-4516             | MIMAT0019053             | Up         | 1.1387029            | 0.00619   |
| hsa-miR-4281             | MIMAT0016907             | Up         | 1.0670805            | 0.00732   |
| hsa-miR-6821-5p          | MIMAT0027542             | Up         | 0.9847684            | 0.01431   |
| hsa-miR-92a-3p           | MIMAT0000992             | Down       | $-0.6512084$         | 0.00370   |
| hsa-miR-17-5p            | MIMAT0000070             | Down       | $-0.59740776$        | 0.01058   |

In Figure 2(a). The complete lists of significantly enriched KEGG pathways are reported in Supplementary Tables 1–3.

Interestingly, we found that TNF, MAPK, and WNT signaling pathways were specifically enriched exclusively in the PsA only active subset (Figure 2(a)), whereas they were not significantly overrepresented in the other miRNA subsets. We further focused our attention on TNF signaling genes targeted by the PsA only active miRNA subset. Within this subset, several miRNAs target key molecules of TNF signaling pathway. For example, miR-130a-3p has been reported to target TNF-alpha [21] as well as CREB transcription factor, a downstream mediator of TNF stimuli [22]. MiR-192-5p and miR-199a-5p target IL-6, IL-15, and LIF, key proinflammatory effectors induced by TNF [23]. Furthermore, miR-130a, miR-148a-3p, miR-192a-5p, miR-199a-3p, and miR-126-3p target NF-KB1 and MAPK components. MAP kinases are targets of PsA only active miRNAs: for example, MAPK1, MAP2K3, MAP3K4, and MAP4K3 were reported as miR-148a-3p targets [24–27]. Moreover, we also identified several miRNA target genes belonging to the WNT/beta-catenin pathway: among PsA only active miRNAs, miR-130a-3p targets WNT10B, whereas miR-192-3p targets WNT3. Furthermore, some members of the “frizzled” gene family, transmembrane domain proteins that are receptors for WNT signaling proteins, such as FZD1, FZD4, and FZD7, are targets of miR-192-5p, whereas miR-130a-3p interacts with FZD3 [26]. A complete description of deregulated miRNAs and their target genes included in the TNF, MAPK, and WNT signaling pathways is shown in Supplementary Tables 4–6.

Interestingly, the KEGG pathway “proteoglycans in cancer” was overrepresented in all the miRNA subsets studied.
Table 3: Differentially expressed miRNAs in PBMC from PsA patients with nonactive disease compared to healthy controls.

| MicroRNA systematic name | miRBase accession number | Regulation | Fold change (log₂) | p (corr) |
|--------------------------|--------------------------|------------|-------------------|---------|
| hsa-miR-4741             | MIMAT0019871             | Up         | 6.5892735         | 0.00002 |
| hsa-miR-638              | MIMAT0003308             | Up         | 4.398291          | 0.00620 |
| hsa-miR-574-5p           | MIMAT0004795             | Up         | 3.7202826         | 0.00412 |
| hsa-miR-1268b            | MIMAT0018925             | Up         | 3.6815526         | 0.00343 |
| hsa-miR-3135b            | MIMAT008985              | Up         | 3.4817348         | 0.00328 |
| hsa-miR-6869-5p          | MIMAT0027638             | Up         | 2.1804085         | 0.00020 |
| hsa-miR-28-5p            | MIMAT0000085             | Down       | -1.8294334        | 0.00498 |
| hsa-miR-7704             | MIMAT0030019             | Up         | 1.5552136         | 0.00430 |
| hsa-miR-590-5p           | MIMAT0003258             | Down       | -1.3467566        | 0.00799 |
| hsa-miR-6125             | MIMAT0024598             | Up         | 1.3346127         | 0.00003 |
| hsa-miR-423-5p           | MIMAT0004748             | Down       | -1.2536168        | 0.00206 |
| hsa-miR-6089             | MIMAT0023714             | Up         | 1.2348131         | 0.00002 |
| hsa-miR-342-5p           | MIMAT004694              | Down       | -1.0435429        | 0.00629 |
| hsa-miR-4530             | MIMAT0019069             | Up         | 0.8868689         | 0.00014 |
| hsa-miR-4516             | MIMAT0019053             | Up         | 0.81782526        | 0.00078 |
| hsa-miR-361-5p           | MIMAT0000703             | Down       | -0.79595757       | 0.00558 |
| hsa-miR-320c             | MIMAT0005793             | Down       | -0.7949343        | 0.00350 |
| hsa-miR-4505             | MIMAT0019041             | Up         | 0.69223696        | 0.00009 |
| hsa-miR-1202             | MIMAT0005865             | Up         | 0.6756515         | 0.00419 |
| hsa-miR-6087             | MIMAT0023712             | Up         | 0.59775305        | 0.00288 |
| hsa-miR-146a-5p          | MIMAT0000449             | Down       | -0.59278536       | 0.00388 |
| hsa-miR-320d             | MIMAT0006764             | Down       | -0.5812883        | 0.00013 |

However, it is important to note that it was the top enriched pathway in PsA only active, whereas its enrichment in the two other subsets was less prominent. Interestingly, the number of miRNA target genes in this pathway was much higher in PsA only active as compared to the other miRNA subsets (Figure 2(b)).

These target genes included AKT1, FGF2, WNT3, WNT5A, and TWIST2. The entire lists of miRNA target genes that are members of the proteoglycans in cancer pathway are reported in Supplementary Table 7.

3.3. Comparison of Deregulated miRNAs with Differentially Expressed Genes in PsA. In a previous work, we investigated PsA-associated transcriptional profiles by a gene expression analysis of peripheral blood cells and synovial biopsies derived from paired PsA patients and identified genes modulation strictly connected to the disease pathogenesis [8]. In this study, we aimed to complement this gene expression analysis detecting modulated miRNAs that may target differentially expressed genes (DEGs) identified in our previous analysis.

To this purpose, the list of miRNA targets was compared to the list of DEGs identified in blood samples of PsA patients. Since in our previous study we had enrolled patients with an active disease, for this comparison we excluded target genes of the PsA only nonactive miRNA list. According to Tarbase, we observed that the ~43% of these PsA-associated DEGs were targeted by deregulated miRNAs identified in the present study. We found that 24.9% of these genes showed an opposite modulation with respect to their targeting miRNAs (Figure 3(a)).

Interestingly, we found that several downmodulated miRNAs, such as miR-130a-3p, miR-126-3p, and miR-192-5p, targeted crucial molecules upregulated in PsA. Indeed, miR-130a-3p targeted TNF-alpha, miR-126-3p targeted osteopontin (SPP1) [28], and both miR-130a-3p and miR-192-5p targeted interleukin-6 signal transducer molecule (IL-6ST). Notably, miR-126-3p was the most downregulated miRNA in our PsA patients.

The complete list of DEGs inversely deregulated with respect to their associated targeting miRNAs is shown in Supplementary Table 8.

Our previous gene expression study in PsA was then complemented by a more sophisticated network analysis in which the functional interactions between the protein products of modulated genes have been evaluated. By this approach, a protein-protein interaction (PPI) network comprising 291 genes (nodes) and 535 pairs of interactions (edges) was constructed (Figure 3(b)). The obtained PPI-network was submitted to a modular analysis to highlight clusters of densely interconnected nodes (modules) that are expected to be involved in common biological processes and to have a prominent role in the disease pathogenesis. This analysis detected the presence of five modules (k = 5) that are graphically represented in Figure 3(c). For each module, a functional enrichment analysis
was performed to identify the most represented biological classes and signaling pathways. We found that the most enriched biological processes (BP) included glycosaminoglycan catabolic process (module M0, p value < 0.0001), type I interferon signaling (module M1, p value < 0.0001), inflammatory response (module M2, p value < 0.0001), extracellular matrix organization (module M3, p value < 0.0001), and positive regulation of activated T-cell proliferation (module M4, p value = 0.0026). Interestingly, in module M2 the “T-helper 17 cell immune response” process was significantly enriched (p value = 0.0151). Indeed, in this module we found the presence of several Th-17 cells associated genes including C-X-C motif chemokine ligand 1, 2, and 13 (CXCL1, 2, and 13), TNF, interleukin-8, 17A, 18, and 23A (IL8, 17A, 18, and 23A), C-C chemokine receptor type 6 (CCR6), C-C motif chemokine ligand 20 (CCL20), secreted protein acidic and cysteine rich (SPARC), interleukin-12 receptor subunit beta-1 (IL12RB1), matrix metalloproteinase-9 (MMP9), and signal transducer and activator of transcription 3 (STAT3).

Moreover, we also have to mention that in module M4 we observed an enrichment in the “positive regulation of T-helper 17 cell lineage commitment” BP (p value = 0.0164) due to the presence of Th-17 cells related genes such as IL12RB1, IL23A, and STAT3. Furthermore, with agreement to the TNF-driven inflammatory response typical of PsA, we found the enrichment of “positive regulation of tumor necrosis factor production” BP in module M4 (p value = 0.0267). Several pathways were also enriched in the five modules, including Toll-like receptor (module M1, p value = 0.0310), inflammation mediated by chemokine and cytokine (module M2, p value < 0.0001), integrin (module M3, p value < 0.0001), and interleukin (module M4, p value < 0.0001) signaling pathways. Noteworthy, in module M4 we observed the enrichment of p38 MAPK and B-cell activation signaling pathways (p values < 0.0002 and 0.037, resp.). All the enriched functional categories for each module are shown in Supplementary Table 9.

Notably, we observed that several upregulated genes present in various modules were also targets of modulated miRNAs in PsA samples, including SDC2 (M0), SDC4 (M0, M3), IFIHI1 (M1), CXCL2 (M2), MMP9 (M2), SPP1 (M2, M3), COL4A3 (M3) and LAMC1 (M3), and IL6ST (M4).

All the genes targeted in the modules by deregulated miRNAs are highlighted in Figure 3(c). Interestingly, we observed that M0 and M3 modules included a higher percentage of “nodes” targeted by miRNAs, with 75% and 70% of targeted
3.4. Biological Processes Altered in PsA Are Targeted by Deregulated miRNAs in Active Disease. Since the PsA only active miRNA subset was specifically associated with the active disease, we decided to further study this subset to identify miRNAs potentially relevant in PsA pathogenesis. To this purpose, we selected Gene Ontology (GO) terms from Biological Process Ontology representing functional classes altered in PsA and we verified whether they were targeted by PsA only active miRNAs. The choice of GO terms was based on the functional classes that we found altered by gene expression profiling in PsA patients and on the pathogenic features typically associated with PsA such as inflammation, activation of innate and adaptive immunity (particularly T-cells), angiogenesis, apoptosis, and bone remodeling [3,8].

Then, we used the reverse search function of DIANA-miRPath to find the PsA only active miRNAs significantly targeting the GO terms of interest. For each miRNA, the percentages of genes targeted in the selected BPs were represented in the heat-map of Figure 4. Interestingly, we found a restricted group of 11 miRNAs (miR-126-3p, miR-151a-5p, miR-130a-3p and miR-199a-3p, miR-192-5p, miR-148a-3p, miR-199a-5p, miR-331-3p, miR-92a-3p, miR-17-5p) with experimentally validated targets for the vast majority of the selected BPs. It is important to note
Figure 3: Comparison of deregulated miRNAs target genes with PsA-associated transcriptional profiles. (a) Pie chart showing percentages of DEGs in PsA from [8] not targeted or targeted by PsA only active and PsA common deregulated miRNAs. DEGs targeted by two or more miRNAs with different modulation in PsA (up- and downmodulated) are defined as "targeting: both opposite and concordant." (b) Protein-protein interaction (PPI) network of DEGs in PsA patients (from [8]). (c) Modules originated from the interaction network. Genes targeted by deregulated miRNAs are highlighted in red.
that, within this subset, \( \text{miR-126-3p}, \text{miR-151a-5p}, \text{miR-130a-3p}, \text{and miR-199a-3p} \) had the highest fold changes in our microarray analysis.

### 3.5. Validation of Deregulated miRNAs by Real-Time PCR

Selected miRNAs significantly deregulated in the microarray analysis were validated by real-time PCR in the entire series of patients analyzed. We focused on miRNAs belonging to the restricted group of 11 \textit{PsA only active} miRNAs identified as targeting biological processes altered in PsA (Figure 4) and with a high FC in the microarray analysis (FC > |10|). Based on these criteria, we selected \( \text{miR-126-3p}, \text{miR-151a-5p}, \text{miR-130a-3p}, \text{and miR-148a-3p} \) for PCR validations.

A significant downmodulation of all the selected miRNAs in active PsA samples was confirmed, albeit with lower FC than microarray data (Figure 5(a)). In addition, real-time PCR analysis revealed that \( \text{miR-148a-3p} \) was significantly downregulated also in remission samples as compared to healthy controls. The expression of the miRNAs was also evaluated in 7 PBMC samples derived from RA to verify whether their underexpression could be also associated with other inflammatory arthritides. We found that \( \text{miR-126-3p}, \text{miR-148a-3p}, \text{and miR-130a-3p} \) were significantly underexpressed also in RA samples (Figure 5(a)).

Furthermore, since \( \text{miR-126-3p} \) was the miRNA with the highest FC in our series of patients, we decided to perform a real-time PCR analysis in an expanded panel of PsA patients and control healthy donors. We confirmed that \( \text{miR-126-3p} \) expression was significantly reduced in the expanded group of active PsA samples (11 patients) as compared to healthy controls (15 subjects) (FC: −3.7; Figure 5(b)). In addition, we found that \( \text{miR-126-3p} \) reduced expression in remission patients (12 subjects) was statistically significant in the expanded cohort (FC: −1.9). Interestingly, higher \( \text{miR-126-3p} \) expression levels were detected in remission samples when compared to active PsA (FC: 1.9) (Figure 5(b)).

### 3.6. Identification of Novel \textit{miR-126-3p} Targets

A precise role for \( \text{miR-126} \) in PsA has not been identified so far. Since \( \text{miR-126-3p} \) expression was reduced in PBMC of active PsA patients and its level was raised in nonactive patients, we can speculate that this miRNA may have an important regulatory function in the disease.

We therefore sought for putative \( \text{miR-126} \) targets with a potential role in PsA pathogenesis. To this purpose, we performed an analysis with TargetScan software, a bioinformatics tool able to predict putative miRNA targets by searching for the presence of 3’ untranslated region sites that match the seed sequence of each miRNA [29]. We narrowed down the analysis on novel predicted gene targets that belong to molecular pathways relevant for PsA pathogenesis. Thus, we selected these four potential targets: \textit{v-akt murine thymoma viral oncogene homolog 2 (AKT2)}, \textit{protein phosphatase 3 catalytic subunit beta (PPP3CB)}, \textit{tumor necrosis factor ligand superfamily member 11 (TNFSF11, also known as RANKL)}, and \textit{syndecan 2 (SDC2)} genes (Supplementary Table 10).

To assess whether \( \text{miR-126-3p} \) was able to regulate these putative target genes, we transfected the T-cell leukemia cell...
line Jurkat with a miR-126-3p mimic and we evaluated the impact of its ectopic expression on AKT2, PPP3CB, RANKL, and SDC2 transcript levels. We used PIK3R2 as positive control of the miRNA mimic, since it is a well-known miR-126-3p target [30]. After 48 hours from transfection, miR-126-transfected cells expressed significantly lower levels of all the targets as compared to the mimic control (Figure 5(d)). These results indicate that miR-126-3p may control the expression of these genes by the downregulation of their transcripts.

4. Discussion

A systematic analysis of miRNA expression profiles in PsA has not been performed yet; in particular, it is not known
whether the global miRNA expression varies in the active disease when compared to the disease in remission phase. We therefore analyzed global miRNA expression profiles in patients with active PsA and in patients that were in a remission phase of the disease, to identify miRNAs associated with PsA and, eventually, miRNAs specifically associated with the active stage of the disease. By this approach, we were able to distinguish three subsets of miRNAs that were differentially expressed only in active (PsA only active) or only in nonactive PsA (PsA only nonactive) or that are commonly deregulated in the two conditions (PsA common). Interestingly, miRNAs belonging to the last group were consensually modulated in active and in nonactive PsA and we found that all the miRNAs subsets mostly targeted signaling pathways that have been already described in PsA, including pathways associated with proteoglycans metabolism [20]. Moreover, modulated miRNAs in PsA targeted pathways with a potential implication for the disease, related to the immune system and to crucial signaling pathways governing cell proliferation and/or apoptosis.

Noteworthy, we found that TNF, MAPK, and WNT signaling pathways, which have been implicated in PsA pathogenesis [8], were significantly targeted by miRNAs modulated only in the active form of the disease. TNF signaling pathway plays a crucial role in PsA and therapeutic TNF neutralization is a commonplace practice in the treatment of the disease [1]. Interestingly, different members of MAP kinase pathway were described as upregulated in blood and in inflamed synovial samples derived from PsA patients [8] and the p38 MAPK signaling pathway has been associated with psoriasis and PsA [31]. Moreover, the WNT signal cascade has been implicated in synovial inflammation and in pathological bone remodeling [32]. In addition, altered expression of several members of WNT signaling pathway has been also demonstrated in PsA patients [8].

We also observed that the KEGG pathway "proteoglycans in cancer" was significantly targeted by all the subsets of modulated miRNAs, and it was the top enriched pathway in PsA only active miRNAs subset. Although the pathway is typically associated with many types of cancers, proteoglycans play key roles in angiogenesis, in extracellular matrix metabolism and in the migration and retention of leukocytes, whose deregulation is hallmarks of chronically inflamed synovium typical of PsA [20]. Among gene targets of PsA only active miRNAs belonging to this pathway, AKT1, FGF2, WNT3, WNT5A, and TWIST2 are involved in active bone and cartilage development and in bone remodeling, which are typical features of the active disease. This finding suggested that proteoglycans metabolism could be importantly affected by miRNAs deregulation in PsA, in particular during the active phase of the disease.

Our data pretty well correlated to the results we previously published describing gene modulation associated with PsA patients [8]. Indeed, ~43% of differentially expressed genes (DEGs) that we described in PsA were targeted by modulated miRNAs that we identified in the present work. These genes included molecules that play important role in the PsA pathogenesis and that were upregulated in our previous analysis (i.e., TNF-alpha, SPPI, and IL6ST). Interestingly, all these molecules were targeted by downmodulated miRNAs like miR-130a-3p (TNF-alpha, IL6ST), miR-126-3p (SPPI), and miR-192-5p (IL6ST); this was coherent with the typical miRNA action as negative regulator of gene expression (i.e., overexpressed genes are targeted by downregulated miRNAs and downmodulated genes are targeted by upregulated miRNAs).

TNF-alpha is involved in a number of autoimmune/inflammatory diseases and is one of the major proinflammatory factors in arthritis causing joint inflammation and cartilage destruction. Furthermore, TNF level is increased both in the synovium and in the synovial fluid of PSA patients [6].

We have previously demonstrated that high serum levels of SPPI were detectable in PsA and in other inflammatory arthritides [8]. Thus, downregulation of miR-126-3p could explain, at least in part, the molecular mechanism underlying the upregulation of SPPI in PsA. Finally, IL6ST has a key role in the differentiation of Th17 cells and was found upregulated in PsA patients [8].

To prioritize modulated genes in PsA that may play a prominent role in the pathogenesis of this disease, the results of our previous gene expression analysis were submitted to a network analysis and we identified five modules that included the most highly connected genes. The functional enrichment analysis of modules confirmed their involvement in biological processes and pathways that are crucial in the PsA pathogenesis including type I interferon signaling, inflammatory response, extracellular matrix organization, regulation of activated T-cell proliferation, T-helper 17 cell (Th-17) immune response, TNF-alpha production and Toll-like receptors, p38 MAPK, and B-cell activation signaling pathways. Interestingly, in each module, we found genes that are targets of miRNAs modulated in PsA.

These results strengthen the pathogenetic relevance of some miRNAs since they target components of modules where genes associated with an autoimmune response are strictly connected, including genes associated with IFN response, or with Th-17 cell immune response.

In particular, beside SPPI and IL6ST, modulated miRNAs targeted important genes in modules like SDC2, SDC4, CXCL12, and MMP9. CXCL2 is another target with a potential interest, since it is a chemokine produced by monocytes and macrophages following stimulation by IL-17. Besides its role as chemotaxing molecule for neutrophils, CXCL2 has been associated with increased osteoclastogenesis in rheumatoid arthritis-associated bone erosion [33]. The matrix metalloprotease MMP9 expression is found elevated in arthritis and this enzyme degrades noncollagen matrix component of the joint [34].

In particular, we observed that the two modules that were involved in glycosaminoglycan metabolism and extracellular matrix organization, whose alteration is crucial in the pathogenesis of inflammatory arthritis [8], were mostly impacted by modulated miRNAs. Indeed, among other modules, they included the highest number of gene targets. Moreover, considering that proteoglycans in cancer were the top enriched
pathway for PsA only active miRNAs, it is tempting to spec-
ulate that epigenetics dysregulation mediated by miRNAs could
counter a major influence in proteoglycans metabolism
and extracellular matrix organization in PsA. Indeed, some
evidence in literature suggests a role for miRNAs in the reg-
ulation of extracellular matrix degradation in osteoarthritis
chondrocytes [35]. In addition, it is known that miRNAs play
an important role in inflammatory response, synovial cell
proliferation, and production of matrix metalloproteases in
RA synovial tissues [11]. Further studies would be needed
to better clarify the role of miRNAs in cartilage and bone
remodeling in PsA.

We then focused our attention on PsA only active subset
and searching for miRNAs that may target relevant functional
classes that we found altered in our previous gene expression
analysis. We could select 11 miRNAs that targeted the vast
majority of selected BPs and, among these, miR-126-3p, miR-
151a-5p, miR-130a-3p, and miR-199a-3p showed the highest
cold changes.

A precise role for the above-mentioned miRNAs in
inflammatory arthritides has not been clearly elucidated yet.
Some evidence indicates that miR-126 can regulate vascular
integrity and angiogenesis by downregulating SRED1 and
PIK3R2 [36], and vascular changes typically occurred in joint
lesions of PsA [1, 3]. Interestingly, a decreased expression
of miR-130a has been shown to correlate with TNF-
lesions of PsA [1, 3]. Interestingly, a decreased expression
of miR-126-3p in PsA may act as calcineurin inhibitors. Altogether, our results suggest
that the reduced expression of miR-126-3p in PsA may
have important functional consequences upon regulation of
molecular targets with a relevant role in PsA pathogenesis.

In conclusion, this work represents the first study which
combines a comprehensive miRNA expression profiling with
a transcriptome analysis in PsA. By microarray analysis, we
identified specific miRNA expression profiles that character-
ize PsA patients both in active disease and in remission phase.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Antonio Puccetti, Andrea Pelosi, Claudio Lunardi, and
Marzia Dolcino conceived and designed the experiments.
Andrea Pelosi and Marzia Dolcino performed the experi-
ments. Andrea Pelosi and Marzia Dolcino analyzed the data.
Giuseppe Patuzzo, Giuseppe Argentino, and Piera Filomena Fiore contributed reagents. Elisa Tinazzi and Francesca

...
Moretta contributed materials. Andrea Pelosi wrote the paper. Antonio Puccetti and Marzia Dolcino equally contributed. Andrea Pelosi wrote the paper.

**Supplementary Materials**

**Supplementary Table 1.** KEGG pathway enrichment analysis in PsA only active miRNAs subset.

**Supplementary Table 2.** KEGG pathway enrichment analysis in PsA common miRNAs subset.

**Supplementary Table 3.** KEGG pathway enrichment analysis in PsA nonactive miRNAs subset.

**Supplementary Table 4.** TNF signaling pathway target genes of PsA only active miRNAs.

**Supplementary Table 5.** MAPK signaling pathway target genes of PsA only active miRNAs.

**Supplementary Table 6.** Target genes of PsA only active miRNAs subset belonging to WNT signaling pathway.

**Supplementary Table 7.** "Proteoglycans in cancer" target gene list for PsA only active, PsA common, and PsA only nonactive miRNA subsets.

**Supplementary Table 8.** List of DEGs and their corresponding targeting miRNAs inversely modulated in PsA.

**Supplementary Table 9.** Functional enrichment analysis of PsA modules.

**Supplementary Table 10.** TargetScan analysis for the identification of novel miR-126-3p Targets.

**Supplementary Figure 1.** Hierarchical clustering analysis of differentially expressed microRNAs in active and nonactive PsA.

**References**

[1] C. T. Ritchlin, R. A. Colbertrand, and D. D. Gladman, "Psoriatic arthritis," *England Journal of Medicine*, vol. 376, pp. 2095-2096, 2017.
[2] P. Rahmanand and J. T. Elder, "Genetic epidemiology of psoriasis and psoriatic arthritis," *Annals of the Rheumatic Diseases*, vol. 2, pp. 137–139, 2005.
[3] O. FitzGerald and R. Winchester, "Psoriatic arthritis: from pathogenesis to therapy," *Arthritis Research & Therapy*, vol. 11, no. 1, article 214, 2009.
[4] J. M. H. Moll and V. Wright, "Psoriatic arthritis," *Seminars in Arthritis and Rheumatism*, vol. 3, no. 1, pp. 55–78, 1973.
[5] P. Mease, "Psoriatic arthritis and spondylarthropathies: assessment and management update," *Current Opinion in Rheumatology*, vol. 25, no. 3, pp. 287–296, 2013.
[6] H. Robinson, S. Kelly, and C. Pitzalis, "Basic synovial biology and immunopathology in psoriatic arthritis," *The Journal of Rheumatology*, vol. 36, no. 83, pp. 14–16, 2009.
[7] L. Costa, C. Perricone, M. S. Chimienti et al., "Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence," *Drugs in R&D*, vol. 17, no. 4, pp. 509–522, 2017.
[8] M. Dolcino, A. Ottria, A. Barbieri et al., "Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis," *PLoS ONE*, vol. 10, no. 6, Article ID e0128262, 2015.
[9] A. Mehta and D. Baltimore, "MicroRNAs as regulatory elements in immune system logic," *Nature Reviews Immunology*, vol. 16, no. 5, pp. 279–294, 2016.
[10] Z. Qu, W. Li, and B. Fu, "MicroRNAs in Autoimmune Diseases," *BioMed Research International*, vol. 2014, Article ID 527895, 8 pages, 2014.
[11] T. Nakasa, Y. Nagata, K. Yamasaki, and M. Ochi, "A mini-review: microRNA in arthritis," *Physiological Genomics*, vol. 43, no. 10, pp. 566–570, 2011.
[12] G. Ciancio, M. Ferracin, and E. Saccenti, "Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis," *Clin Exp Rheumatol*, vol. 35, pp. 113–121, 2017.
[13] D. Aletaha, T. Neogi, A. J. Silman et al., "rheumatoid arthritis classification criteria: An american college of rheumatology/european league against rheumatism collaborative initiative," *Arthritis Rheum*, vol. 62, pp. 2569–2589, 2010.
[14] I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni et al., "DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions," *Nucleic Acids Research*, vol. 43, no. 1, pp. D153–D159, 2015.
[15] I. S. Vlachos, K. Zagganas, M. D. Paraskevopoulou et al., "DIANA-miRPath v3.0: deciphering microRNA function with experimental support," *Nucleic Acids Research*, vol. 43, no. W1, pp. W460–W466, 2015.
[16] A. Franceschini, D. Szklarczyk, S. Frankild et al., "STRING v9.1: protein-protein interaction networks, with increased coverage and integration," *Nucleic Acids Research*, vol. 41, no. 1, pp. D808–D815, 2013.
[17] M. Dolcino, E. Tinazzi, A. Pelosi et al., "Gene expression analysis before and after treatment with adalimumab in patients with ankylosing spondylitis identifies molecular pathways associated with response to therapy," *Gene*, vol. 8, no. 4, article no. 127, 2017.
[18] V. F. Viprey, M. V. Corrias, and S. A. Burchill, "Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling," *Analytical Biochemistry*, vol. 421, no. 2, pp. 566–572, 2012.
[19] M. Xiang, Y. Zeng, R. Yang et al., "U6 is not a suitable endogenous control for the quantification of circulating microRNAs," *Biochemical and Biophysical Research Communications*, vol. 454, no. 1, pp. 210–214, 2014.
[20] A. M. Patterson, A. Cartwright, G. David et al., "Differential expression of syndecans and glypican in chronically inflamed synovium," *Annals of the Rheumatic Diseases*, vol. 67, no. 5, pp. 592–601, 2008.
[21] J. Zhang, H. Wu, P. Li, Y. Zhao, M. Liu, and H. Tang, "NF-kB-modulated miR-130a targets TNF-α in cervical cancer cells," *Journal of Translational Medicine*, vol. 12, no. 1, pp. 155, 2014.
[22] A. Y. Wen, K. M. Sakamoto, and L. S. Miller, "The role of the transcription factor CREB in immune function," *The Journal of Immunology*, vol. 185, no. 11, pp. 6413–6419, 2010.
[23] S. Y. Wu, R. Rupaimoole, F. Shen et al., "A mir-192-egfr-hoxb9 regulatory network controls the angiogenic switch in cancer," *Nat Commun*, vol. 7, p. 11169, 2016.
[24] A. Helwak, G. Kudla, T. Dudnakova, and D. Tollervey, "Mapping the human microRNA interactome by CLASH reveals frequent noncanonical binding," *Cell*, vol. 153, no. 3, pp. 654–665, 2013.
[25] F. V. Karginov and G. J. Hannon, "Remodeling of Ago2-mRNA interactions upon cellular stress reflects miRNA complementarity and correlates with altered translation rates," *Genes & Development*, vol. 27, no. 14, pp. 1624–1632, 2013.
[26] M. M. Pillai, A. E. Gillen, T. M. Yamamoto et al., "HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer," *Breast Cancer Research and Treatment*, vol. 146, no. 1, pp. 85–97, 2014.

[27] A. W. Whisnant, H. P. Bogerd, O. Flores et al., "In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms," *MBio*, vol. 4, no. 2, Article ID e00193-13, 2013.

[28] N. Felli, F. Felicetti, A. M. Lustri et al., "Mir-126&126∗ restored expressions play a tumor suppressor role by directly regulating adam9 and mmp7 in melanoma," *PLoS One*, vol. 8, Article ID 126126, p. e56824, 2013.

[29] V. Agarwal, G. W. Bell, J.-W. Nam, and D. P. Bartel, "Predicting effective microRNA target sites in mammalian mRNAs," *eLife*, vol. 4, no. 2015, Article ID e05005, 2015.

[30] X.-J. Wu, Z.-F. Zhao, X.-J. Kang, H.-J. Wang, J. Zhao, and X.-M. Pu, "MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi’s sarcoma cells," *Oncotarget*, vol. 7, no. 24, pp. 36614–36621, 2016.

[31] A. Mavropoulos, E. I. Rigopoulou, C. Liaskos, D. P. Bogdanos, and L. I. Sakkas, "The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis," *Clinical and Developmental Immunology*, vol. 2013, Article ID 569751, 8 pages, 2013.

[32] C.-G. Miao, Y.-Y. Yang, X. He et al., "Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling," *Cellular Signalling*, vol. 25, no. 10, pp. 2069–2078, 2013.

[33] J. Ha, H.-S. Choi, Y. Lee, H.-J. Kwon, Y. W. Song, and H.-H. Kim, "CXCL chemokine ligand 2 induced by receptor activator of NF-κB ligand enhances osteoclastogenesis," *The Journal of Immunology*, vol. 184, no. 9, pp. 4717–4724, 2010.

[34] P. S. Burrage, K. S. Mix, and C. E. Brinckerhoff, "Matrix metalloproteinases: role in arthritis," *Frontiers in Bioscience*, vol. 11, no. 1, pp. 529–543, 2006.

[35] N. Akhtar, Z. Rasheed, S. Ramamurthy, A. N. Anbazhagan, F. R. Voss, and T. M. Haqqi, "MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes," *Arthritis & Rheumatology*, vol. 62, no. 5, pp. 1361–1371, 2010.

[36] J. E. Fish, M. M. Santoro, S. U. Morton et al., "miR-126 regulates angiogenic signaling and vascular integrity," *Developmental Cell*, vol. 15, no. 2, pp. 272–284, 2008.

[37] Z. C. Li, N. Han, X. Li et al., "Decreased expression of microRNA-130a correlates with Tnf-alpha in the development of osteoarthritis," *Int J Clin Exp Pathol*, vol. 8, pp. 2555–2564, 2015.

[38] I. Daugaard, K. J. Sanders, A. Idica et al., "miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells," *Oncogenesis*, vol. 6, no. 7, p. e366, 2017.

[39] E. A. Lin, L. Kong, X.-H. Bai, Y. Luan, and C.-J. Liu, "miR-199a*, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1," *The Journal of Biological Chemistry*, vol. 284, no. 17, pp. 11326–11335, 2009.

[40] C. J. Malemud, "The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?" *Future Medicinal Chemistry*, vol. 7, no. 9, pp. 1137–1147, 2015.

[41] D. Dutta, V. A. Barr, I. Akpan et al., "Recruitment of calcineurin to the TCR positively regulates T cell activation," *Nature Immunology*, vol. 18, no. 2, pp. 196–204, 2017.
